$1.09
-0.04(-3.54%)
Mkt Cap $24M
$1.01
$1.76
52-Week Range
At a Glance
AI-generatedBoundless Bio, Inc.
8-K
Boundless Bio, Inc. announced Q4 and full year 2025 financial results with net loss of $12.9 million and $58.2 million respectively, cash of $107.6 million providing runway into second half of 2028, and KOMODO-1 trial of BBI-940 open for enrollment. Christine Brennan, Ph.D. resigned from the Board effective March 3, 2026, for a new role at Johnson & Johnson Development Corporation with no disagreements.$24M
Market Cap
—
Revenue
-$58M
Net Income
Employees64
Fundamentals
How The Business Makes Money
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001782303
ISINUS10170A1007
CUSIP10170A100
Phone858 766 9912
Address9880 Campus Point Drive, San Diego, CA, 92121, US
SEC EDGAR